GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bioptik Technology Inc (ROCO:4161) » Definitions » Debt-to-EBITDA

Bioptik Technology (ROCO:4161) Debt-to-EBITDA : 2.45 (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Bioptik Technology Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bioptik Technology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$318.4 Mil. Bioptik Technology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$132.7 Mil. Bioptik Technology's annualized EBITDA for the quarter that ended in Dec. 2024 was NT$184.1 Mil. Bioptik Technology's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was 2.45.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Bioptik Technology's Debt-to-EBITDA or its related term are showing as below:

ROCO:4161' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1049.46   Med: 5.45   Max: 13.2
Current: 2.91

During the past 13 years, the highest Debt-to-EBITDA Ratio of Bioptik Technology was 13.20. The lowest was -1049.46. And the median was 5.45.

ROCO:4161's Debt-to-EBITDA is ranked worse than
70.63% of 446 companies
in the Medical Devices & Instruments industry
Industry Median: 1.47 vs ROCO:4161: 2.91

Bioptik Technology Debt-to-EBITDA Historical Data

The historical data trend for Bioptik Technology's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioptik Technology Debt-to-EBITDA Chart

Bioptik Technology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -36.66 10.65 6.29 3.44 2.91

Bioptik Technology Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.38 4.07 3.05 3.80 2.45

Competitive Comparison of Bioptik Technology's Debt-to-EBITDA

For the Medical Devices subindustry, Bioptik Technology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioptik Technology's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bioptik Technology's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Bioptik Technology's Debt-to-EBITDA falls into.


;
;

Bioptik Technology Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bioptik Technology's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(318.362 + 132.661) / 155.097
=2.91

Bioptik Technology's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(318.362 + 132.661) / 184.112
=2.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.


Bioptik Technology  (ROCO:4161) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Bioptik Technology Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Bioptik Technology's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioptik Technology Business Description

Traded in Other Exchanges
N/A
Address
No.188, Zhonghua South Road, Miaoli County, Zhunan, TWN, 35057
Bioptik Technology Inc is a Taiwan-based company engaged in the research, development, production, and sale of medical devices and reagents. The company is also focused on developing skin care products and aims to engage in developing bioenergy, Astaxanthin, and Cellulose Bioethanol. It is involved in the business areas of Home care medical devices, Skincare- Its own brand, Dietary supplement OEM and ODM, Skincare- OEM and ODM, and Biodiesel. In the Home care business area, the company provides Easy Touch blood glucose monitoring, and blood cholesterol and uric acid monitoring systems, as well as its strips.

Bioptik Technology Headlines

No Headlines